No Prescription |
 |
 | ||
|
Accu Chek Multiclix |
|
| ||
No Prescription » Prescription Drugs 1 » Accu Chek Multiclix Reduce the pain and hassle of testing. Unlike conventional lancing systems the ACCU-CHEK Multiclix lancet device is the only one with a six-lancet drum. It offers the least painful testing * with less hassle and improved safety. With 11 depth settings for maximum comfort and no side-to-side motion for less skin tearing.Self-contained six-lancet drums. No more lancets to see or handle. Just load the six-lancet drum and go.Personalized comfort. With 11 depth settings on the Comfort Dial you can adjust the lancet depth to match your skin type and obtain just enough blood for accurate testing.Precise lancing movement. A precise linear sliding motion reduces the lancet's side-to-side movement and tearing of your skin providing greater comfort.Precisely manufactured lancets. Careful manufacturing and grinding ensure that your lancets will not have bent or broken tips which can result in more painful testing. Buy Accu Chek Multiclix and other Prescription Drugs 1 products online at Medstore. Buy Online at Medstore - Click Here!
About Accu Chek Multiclix: Product Type: Prescription Drugs 1 Accu-Chek Multiclix Accu-Chek Multiclix Accu-Chek Multiclix Lancing Lancing 24 LNCTS Device + 12 LNCTS Accu-Chek Multiclix Accu-Chek Multiclix
View more Prescription Drugs 1 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
